Paltrox rx therapies are
far more valuable than unwanted estrogen alone among postmenopausal females.
Most females have reported more frequent intercourse, higher attention in sex
and improved clitoral understanding on androgenic hormone or testosterone. Some
females have also been noted to acquire less despression symptoms and fatigue
than those on unwanted estrogen alone. However, because androgenic hormone or
testosterone brings to females have not been widely examined and no androgenic
hormone or testosterone therapy has been approved by the FDA for the therapies
for females hypoactive sexual interest disorder HSDD, most doctors apparently
prescribe the hormone "offlabel".